+1,837.5%
SNDK vs MRNA
+485.7%
+1,351.8%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | +5.4% | -8.9% | -3.6% |
| 7D | -6.1% | -1.1% | -5.0% | -6.1% |
| 30D | +21.5% | +126.1% | -104.6% | +17.0% |
| 3M | -13.2% | +190.0% | -203.2% | -28.7% |
| 6M | +149.2% | +157.2% | -8.0% | +115.1% |
| YTD | +588.1% | +388.2% | +199.9% | +311.7% |
| 1Y | +1,837.5% | +467.0% | +1,370.5% | +982.1% |
| All | +1,837.5% | +485.7% | +1,351.8% | +982.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling